The three Centers for Innovation in Advanced Development and Manufacturing will develop vaccines and drugs to respond to bioterrorism attacks, pandemic influenza and other public health emergencies.
HHS estimates the project will cost $400 million in the initial phase and the facilities will become operational in 2014 and 2015.
Secretary Kathleen Sebelius said in the release that the centers will help fill gaps in preparedness.
Emergent Manufacturing Operations Baltimore LLC will run facilities in Baltimore and Gaithersburg, Md. and work with Michigan State University, Kettering University and the University of Maryland.
Novartis will be in charge of the second facility, located in Holly Springs, N.C., and coordinate with North Carolina State University and Duke University.
The Texas A&M University System will head a third center and collaborate with GlaxoSmithKline Vaccines, Lonza, Kalon Biotherapeutics of College Station Texas.